NVS Stock Summary and Trading Ideas (Novartis Ag | NYSE:NVS)

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Novartis Ag trades on the NYSE stock market under the symbol NVS.

As of March 20, 2026, NVS stock price declined to $146.03 with 1,800,549 million shares trading.

NVS has a beta of 0.48, meaning it tends to be less sensitive to market movements. NVS has a correlation of 0.14 to the broad based SPY ETF.

NVS has a market cap of $280.20 billion. This is considered a Mega Cap stock.

Last quarter Novartis Ag reported $13 billion in Revenue and $2.03 earnings per share. This fell short of revenue expectation by $-590 million and exceeded earnings estimates by $.03.

In the last 3 years, NVS traded as high as $170.46 and as low as $81.96.

The top ETF exchange traded funds that NVS belongs to (by Net Assets): PPH, DFIV, DFIC, DFAI, AVDE.

NVS has outperformed the market in the last year with a return of +33.2%, while the SPY ETF gained +16.6%. In the last 3 month period, NVS beat the market returning +10.8%, while SPY returned -4.4%. However, in the most recent 2 weeks NVS has underperformed the stock market by returning -5.8%, while SPY returned -3.3%.

NVS support price is $145.77 and resistance is $150.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVS shares will trade within this expected range on the day.